Your browser is no longer supported. Please, upgrade your browser.
Settings
PSTX [NASD]
Poseida Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.32 Insider Own0.90% Shs Outstand61.98M Perf Week-8.30%
Market Cap537.36M Forward P/E- EPS next Y-2.42 Insider Trans-49.33% Shs Float37.15M Perf Month-17.27%
Income-139.30M PEG- EPS next Q-0.63 Inst Own51.90% Short Float7.86% Perf Quarter-10.48%
Sales- P/S- EPS this Y-157.60% Inst Trans0.11% Short Ratio15.56 Perf Half Y-6.22%
Book/sh3.67 P/B2.26 EPS next Y2.40% ROA-41.70% Target Price- Perf Year-42.03%
Cash/sh4.17 P/C1.99 EPS next 5Y2.70% ROE-96.10% 52W Range7.63 - 15.79 Perf YTD-24.43%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-47.50% Beta-
Dividend %- Quick Ratio9.90 Sales past 5Y- Gross Margin- 52W Low8.65% ATR0.49
Employees208 Current Ratio9.90 Sales Q/Q- Oper. Margin- RSI (14)40.66 Volatility5.34% 5.83%
OptionableYes Debt/Eq0.13 EPS Q/Q-32.80% Profit Margin- Rel Volume0.54 Prev Close8.49
ShortableYes LT Debt/Eq0.12 EarningsMay 11 AMC Payout- Avg Volume187.74K Price8.29
Recom1.20 SMA20-8.10% SMA50-7.30% SMA200-14.71% Volume102,692 Change-2.36%
May-18-21Initiated BTIG Research Buy $40
Aug-04-20Initiated William Blair Outperform
Aug-04-20Initiated Piper Sandler Overweight $30
Aug-04-20Initiated BofA Securities Buy $20
Jul-26-21 08:00AM  
Jun-02-21 08:00AM  
May-11-21 04:05PM  
08:00AM  
May-06-21 08:00AM  
May-05-21 08:00AM  
Apr-28-21 05:33AM  
Apr-27-21 05:00PM  
Apr-08-21 09:00AM  
Mar-23-21 08:00AM  
Mar-11-21 04:05PM  
Feb-24-21 12:22PM  
09:00AM  
Feb-10-21 08:00AM  
Jan-28-21 03:27AM  
Jan-04-21 08:00AM  
Dec-18-20 08:00AM  
Dec-17-20 08:00AM  
Dec-11-20 09:09PM  
Dec-05-20 01:45PM  
Nov-12-20 04:05PM  
Nov-02-20 08:00AM  
Oct-21-20 08:00AM  
Oct-12-20 01:50PM  
Sep-23-20 07:00AM  
Sep-18-20 08:00AM  
Sep-16-20 09:30AM  
Sep-04-20 11:15AM  
Sep-03-20 09:00AM  
Sep-02-20 01:00PM  
Sep-01-20 11:00PM  
04:09PM  
12:40PM  
11:00AM  
Aug-31-20 09:16AM  
Aug-29-20 07:54PM  
Aug-28-20 04:49PM  
Aug-25-20 10:30PM  
Aug-24-20 05:31PM  
Aug-20-20 05:28PM  
04:05PM  
01:13PM  
Aug-19-20 05:47PM  
03:30PM  
Aug-18-20 02:09AM  
Aug-17-20 04:55PM  
Jul-16-20 09:00AM  
Jul-10-20 11:23AM  
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat relapsed/refractory multiple myeloma patients; P-MUC1C-ALLO1, an allogeneic CAR-T product candidate for multiple solid tumor indications; and P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. It is also developing P-OTC-101, a liver-directed gene therapy for the treatment of ornithine transcarbamylase; and P-MMUT-101, a liver-directed gene therapy for the treatment of methylmalonic acidemia. In addition, the company is developing a portfolio of allogeneic dual CAR product candidates. The company was incorporated in 2014 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ostertag EricChief Executive OfficerJul 02Sale8.9127,542245,2743,446,952Jul 06 05:35 PM
Ostertag EricChief Executive OfficerJul 01Sale9.7720,563200,9013,460,124Jul 06 05:35 PM
Spear Matthew A.Chief Medical OfficerJun 17Option Exercise1.325,0006,61021,485Jun 21 08:02 PM
Spear Matthew A.Chief Medical OfficerJun 11Option Exercise1.324,0005,28820,485Jun 14 06:18 PM
Spear Matthew A.Chief Medical OfficerJun 11Sale9.444,00037,74716,485Jun 14 06:18 PM
Ostertag EricChief Executive OfficerJun 02Sale8.3440,722339,6213,469,958Jun 03 07:21 PM
Ostertag EricChief Executive OfficerJun 01Sale8.6141,194354,6803,489,434Jun 03 07:21 PM
Ostertag EricChief Executive OfficerMay 04Sale8.4435,986303,7223,509,135May 05 07:29 PM
Ostertag EricChief Executive OfficerMay 03Sale9.0118,326165,1173,526,346May 05 07:29 PM
Spear Matthew A.Chief Medical OfficerApr 23Option Exercise1.325,0006,61016,485Apr 23 08:49 PM
Spear Matthew A.Chief Medical OfficerApr 21Option Exercise1.324,0005,28815,485Apr 23 08:49 PM
Spear Matthew A.Chief Medical OfficerApr 21Sale8.444,00033,75211,485Apr 23 08:49 PM
Ostertag EricChief Executive OfficerApr 05Sale9.6657,819558,6683,532,624Apr 05 07:50 PM
Ostertag EricChief Executive OfficerApr 01Sale9.5557,181546,3303,560,277Apr 05 07:50 PM
Ostertag EricChief Executive OfficerMar 02Sale11.5457,060658,4153,590,111Mar 03 07:38 PM
Ostertag EricChief Executive OfficerMar 01Sale11.6757,940676,0463,617,401Mar 03 07:38 PM
Ostertag EricChief Executive OfficerFeb 23Option Exercise1.17111,395130,666542,985Feb 25 07:01 PM
Ostertag EricChief Executive OfficerFeb 16Sale10.00133,1491,332,036200,696Feb 17 05:28 PM
Ostertag EricChief Executive OfficerFeb 10Option Exercise1.2967,53487,119431,590Feb 12 05:03 PM
Ostertag EricChief Executive OfficerFeb 10Sale10.0012,389123,890333,845Feb 12 05:03 PM
Ostertag EricChief Executive OfficerJan 21Sale10.004,46244,620346,234Jan 25 07:42 PM
Spear Matthew A.Chief Medical OfficerJan 15Option Exercise1.327,56410,00011,485Jan 19 05:00 PM
Mylet JohannaSenior Vice President, FinanceJan 15Option Exercise0.304,7281,41826,813Jan 19 05:00 PM
Spear Matthew A.Chief Medical OfficerJan 08Option Exercise1.323,9215,1843,921Jan 11 05:00 PM